Last reviewed · How we verify
17 Hydroxyprogesterone Capronate
At a glance
| Generic name | 17 Hydroxyprogesterone Capronate |
|---|---|
| Sponsor | Assiut University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Progesterone in Expectantly Managed Early-onset Preeclampsia (PHASE4)
- 17OHP-C Dosing Among Obese Pregnant Women (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 17 Hydroxyprogesterone Capronate CI brief — competitive landscape report
- 17 Hydroxyprogesterone Capronate updates RSS · CI watch RSS
- Assiut University portfolio CI